Because the tumor findings, PDC NGS analysis, and PDC drug sensitivity test suggested both ALK-positive cells and BRAF-mutated malignant cells, the combined effect of an ALK-TKI and a BRAF inhibitor was tested on the PDC. The gene discussed is BRAF; the disease is neoplasm.